Genetics of Brugada syndrome

Current Opinion in Cardiology

Volumn 25, Issue 3, 2010, Pages 210-215

  Campuzano, Oscar ^a   Brugada, Ramon ^a   Iglesias, Anna ^a  

^a UNIVERSITY OF GIRONA   (Spain)

Author keywords

Brugada syndrome; Genetics; Sudden cardiac death

Indexed keywords

ANKYRIN; SODIUM CHANNEL NAV1.5;

BRUGADA SYNDROME; DEFIBRILLATOR; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HUMAN; MISSENSE MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; REVIEW; ST SEGMENT ELEVATION;

BRUGADA SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; POLYMORPHISM, GENETIC; POTASSIUM CHANNELS, VOLTAGE-GATED; SODIUM CHANNELS;

EID: 77952241260     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833846ee     Document Type: Review

References (65)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391-1396.
2. Proclemer A, Facchin D, Feruglio GA, Nucifora R. Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report. G Ital Cardiol 1993;23:1211-1218.
3. Ferracci A, Fromer M, Schlapfer J, et al. Primary ventricular fibrillation and early recurrence: apropos of a case of association of right bundle branch block and persistent ST segment elevation. Arch Mal Coeur Vaiss 1994;87:1359-1362.
4. Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997;8:325-331.
5. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-460.
6. Alings M, Wilde A. 'Brugada' syndrome: clinical data and suggested pathophysiological mechanism. Circulation 1999;99:666-673.
7. Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 2000;102:2509-2515.
8. Brugada P, Brugada R, Brugada J. Sudden death in patients and relatives with the syndrome of right bundle branch block, ST segment elevation in the precordial leads V (1) to V (3) and sudden death. Eur Heart J 2000;21:321-326. (Pubitemid 30148304)
9. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293-296.
10. Dumaine R, Towbin JA, Brugada P, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999;85:803-809.
11. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660-1666.
12. Rook MB, Bezzina Alshinawi C, Groenewegen WA, et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res 1999;44:507-517.
13. Deschenes I, Baroudi G, Berthet M, et al. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovasc Res 2000;46:55-65.
14. Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002;106:2514-2519. (Pubitemid 35278811)
15. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101:510-515.
16. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659-670.
17. Probst V, Denjoy I, Meregalli PG, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007;115:2042-2048.
18. Ikeda T, Abe A, Yusu S, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol 2006;17:602-607.
19. Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion. J Electrocardiol 2001;34:345-349.
20. Littmann L, Monroe MH, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000;75:845-849.
21. Vernooy K, Sicouri S, Dumaine R, et al. Genetic and biophysical basis for bupivacaine-induced STsegment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm 2006;3:1074-1078.
22. Priori SG, Napolitano C. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005;112:279-292; discussion 279-292.
23. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) : developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e385-e484.
24. Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002;11:337-345.
25. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat 2003;21:651-652.
26. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999;23:20-21.
27. Cordeiro JM, Barajas-Martinez H, Hong K, et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation 2006;114:2026-2033.
28. Mok NS, Priori SG, Napolitano C, et al. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electrophysiol 2003;14:407-411.
29. Veldkamp MW, Viswanathan PC, Bezzina C, et al. Two distinct congenital arrhythmias evoked by a multidysfunctional Na (+) channel. Circ Res 2000; 86: E91-E97.
30. Weiss R, Barmada MM, Nguyen T, et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation 2002;105:707-713.
31. London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007;116:2260-2268.
32. Van Norstrand DW, Valdivia CR, Tester DJ, et al. Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation 2007;116:2253-2259.
33. Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008;118:2260-2268.
34. Hu D, Barajas-Martinez H, Burashnikov E, et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009;2:270-278. This report described the first mutation associated with the SCN3B gene in patients with ECG BrS.
35. Meadows LS, Isom LL Sodium channels as macromolecular complexes: implications for inherited arrhythmia syndromes. Cardiovasc Res 2005;67:448-458.
36. Cordeiro JM, Marieb M, Pfeiffer R, et al. Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol 2009;46:695-703. This report described the first BrS mutation in CACNB2b resulting in a loss of function responsible for the Brugada phenotype.
37. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115:442-449.
38. Takimoto K, Li D, Nerbonne JM, Levitan ES. Distribution, splicing and glucocorticoid-induced expression of cardiac alpha 1C and alpha 1D voltage-gated Ca2+ channel mRNAs. J Mol Cell Cardiol 1997;29:3035-3042.
39. Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 2005;102:8089-8096; discussion 8086-8088.
40. Van Petegem F, Clark KA, Chatelain FC, Minor DL Jr. Structure of a complex between a voltage-gated calcium channel beta-subunit and an alpha-subunit domain. Nature 2004;429:671-675.
41. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005;57:411-425.
42. 2+ channels expressed in Xenopus oocytes. Pflugers Arch 1998;436:238-247.
43. Cornet V, Bichet D, Sandoz G, et al. Multiple determinants in voltagedependent P/Q calcium channels control their retention in the endoplasmic reticulum. Eur J Neurosci 2002;16:883-895.
44. Abbott GW, Butler MH, Bendahhou S, et al. MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. Cell 2001;104:217-231.
45. Abbott GW, Goldstein SA, Sesti F. Do all voltage-gated potassium channels use MiRPs? Circ Res 2001;88:981-983.
46. McCrossan ZA, Lewis A, Panaghie G, et al. MinK-related peptide 2 modulates Kv2.1 and Kv3.1 potassium channels in mammalian brain. J Neurosci 2003;23:8077-8091.
47. Lewis A, McCrossan ZA, Abbott GW. MinK, MiRP1, and MiRP2 diversify Kv3.1 and Kv3.2 potassium channel gating. J Biol Chem 2004;279:7884-7892.
48. Grunnet M, Rasmussen HB, Hay-Schmidt A, et al. KCNE4 is an inhibitory subunit to Kv1.1 and Kv1.3 potassium channels. BiophysJ 2003;85:1525-1537.
49. Bendahhou S, Marionneau C, Haurogne K, et al. In vitro molecular interactions and distribution of KCNE family with KCNQ1 in the human heart. Cardiovasc Res 2005;67:529-538.
50. Abbott GW, Goldstein SA. Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism. FASEB J 2002;16:390-400.
51. Delpon E, Cordeiro JM, Nunez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209-218. Identification of KCNE3 as responsible for BrS.
52. Coronel R, Casini S, Koopmann TT, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005;112:2769-2777.
53. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc Res 2005;67:367-378.
54. Viswanathan PC, Benson DW, Balser JR. A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J Clin Invest 2003;111:341-346.
55. Poelzing S, Forleo C, Samodell M, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation 2006;114:368-376.
56. Lizotte E, Junttila MJ, Dube MP, et al. Genetic modulation of brugada syndrome by a common polymorphism. J Cardiovasc Electrophysiol 2009;20:1137-1141. Description of the common SCN5A variant H558R as a genetic modulator of BrS among carriers of a SCN5A mutation.
57. Bezzina CR, Shimizu W, Yang P, et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 2006;113:338-344.
58. Ito H, Yano K, Chen R, et al. The prevalence and prognosis of a Brugada-type electrocardiogram in a population of middle-aged Japanese-American men with follow-up of three decades. Am J Med Sci 2006;331:25-29.
59. Baroudi G, Acharfi S, Larouche C, Chahine M. Expression and intracellular localization of an SCN5A double mutant R1232W/T1 620M implicated in Brugada syndrome. Circ Res 2002; 90: E11-E16.
60. Makita N, Mochizuki N, Tsutsui H. Absence of a trafficking defect in R1232W/T1620M, a double SCN5A mutant responsible for Brugada syndrome. Circ J 2008;72:1018-1019.
61. Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 2009;6:341-348. This report proposes that the genetic cause, especially the presence of truncated proteins, may be associated with a more severe phenotype.
62. Francis J, Antzelevitch C. Brugada syndrome. Int J Cardiol 2005;101:173-178.
63. Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002;40:1437-1444.
64. Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004;25:879-884.
65. Antzelevitch C. Genetic basis of Brugada syndrome. Heart Rhythm 2007;4:756-757.